Figure 1:
Figure 1:. FFS CMR versus no CMR by landmark analysis for pts who received at least 24.0 months of nilotinib

FFS CMR versus no CMR by landmark analysis for pts who received at least 24.0 months of nilotinib

Close Modal

or Create an Account

Close Modal
Close Modal